Neurocrine Biosciences Goes Dumpster-Diving To Accelerate Its International Business DevelopmentSeeking Alpha • 08/31/22
Neurocrine Is Seeing A Very Welcome Pick Up In Ingrezza, But Pipeline Catalysts Are ThinSeeking Alpha • 08/08/22
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/05/22
Sosei Heptares' Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine BiosciencesGlobeNewsWire • 08/04/22
Neurocrine Biosciences (NBIX) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/04/22
Neurocrine Biosciences Shelves Key Drug; Will It Overshadow The Earnings Beat?Investors Business Daily • 08/04/22
Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales GuidancePRNewsWire • 08/04/22
The Make-Or-Break Moment Is Here For Highly Rated Neurocrine BiosciencesInvestors Business Daily • 07/29/22
Better Ingrezza Sales And A Clinical Trial Read-Out Could Reignite Neurocrine SharesSeeking Alpha • 07/19/22
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial ResultsPRNewsWire • 07/14/22
Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022PRNewsWire • 06/13/22
Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare ConferencePRNewsWire • 06/08/22
Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson's Disease and Motor Fluctuations at SLEEP 2022PRNewsWire • 06/06/22
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022PRNewsWire • 05/23/22
Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington DiseasePRNewsWire • 05/12/22
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/04/22
Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial GuidancePRNewsWire • 05/04/22
Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare ConferencePRNewsWire • 05/03/22
Neurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness WeekPRNewsWire • 05/02/22
Neurocrine Biosciences (NBIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 04/27/22
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial ResultsPRNewsWire • 04/13/22